ORGANOGENESIS HOLDINGS INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.35% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-02-26
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.99%, a 107.81% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 1.92%, a 134.15% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2021-03-31 was 0.82%.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2018-03-31 was 2.73%.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.35%, a 1.87% increase from fiscal 2024.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.27%, a 6.75% increase from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.00%, a 108.33% increase from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.92%, a 131.33% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.35% 10-K · filed 2026-02-26 | |||
| 2024-12-31 | 4.27% 10-K · filed 2026-02-26 | |||
| 2023-12-31 | 4.00% 10-K · filed 2026-02-26 | |||
| 2023-09-30 | 3.99% 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | 3.99% 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | 3.99% 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | 1.92% 10-K · filed 2024-02-29 | |||
| 2022-09-30 | 1.92% 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 1.92% 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | 1.92% 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | 0.83% 10-K · filed 2023-03-01 | |||
| 2021-09-30 | 0.83% 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | 0.82% 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | 0.82% 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | 0.46% 10-K · filed 2022-03-01 | |||
| 2020-09-30 | 0.46% 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | 0.46% 10-Q · filed 2021-08-09 | |||
| 2019-12-31 | 2.24% 10-K · filed 2021-03-16 | |||
| 2019-09-30 | 2.24% 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | 2.24% 10-Q · filed 2019-08-09 | |||
| 2018-12-31 | 2.73% 10-K · filed 2020-03-09 | |||
| 2018-09-30 | 2.74% 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | 2.74% 10-Q · filed 2019-08-09 | |||
| 2018-03-31 | 2.73% 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | 2.05% 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |